A Market Poised for Renewed Momentum: As 2026 unfolds, the women’s health M&A market is entering a period of renewed momentum following two years of calibration and normalization after the 2021-2022 transaction peaks. Multiple macroeconomic and structural forces are converging to support increased deal activity: stabilizing interest rates are improving acquisition financing conditions, record levels of PE dry powder are seeking deployment, improving public equity market conditions are creating a clearer path to future PE exits, and the demographic and structural fundamentals underlying women’s health demand continue to strengthen. KPMG’s 2026 Healthcare & Life Sciences Investment Outlook reports that 67% of healthcare and life sciences dealmakers surveyed anticipated increased M&A activity in 2026.
Platform Activity: The Nine Major Players and What Comes Next
The nine major PE-backed women’s health platforms operating in the U.S. as of early 2026 are at varying stages of their investment cycles. As platforms mature and PE sponsors approach the end of their typical holding periods, secondary sales, larger strategic combinations, and potential public-market exits via IPOs will become increasingly relevant. The reopening of the healthcare IPO market, with Hinge Health and Omada Health going public in the summer of 2025, signaled renewed investor appetite for healthcare services assets, creating a potential exit pathway for the largest and most mature women’s health platforms. This secondary transaction activity will itself generate new investment opportunities as assets are repositioned and repackaged.
Emerging Service Lines: Where Growth Is Going
The platforms that will command the highest exit multiples in the next 5 to 7 years will be those that successfully execute multi-specialty expansion strategies. Fertility services, behavioral health integration, menopause and longevity medicine, and AI-enabled diagnostics are the service categories most frequently cited by investors and operators as the highest-priority growth vectors. The global “FemTech” industry, software and technology addressing women’s biological needs, was expected to grow to $75 billion by 2025 at a 13.3% compound annual growth rate since 2020, and its continued expansion is creating new investment and integration opportunities for clinical platforms. OB/GYN practices that are already building out these service lines today will be more attractive acquisition targets for established platforms—and will benefit from higher multiples that reflect the diversified earnings potential.
Regulatory Environment: Navigating Uncertainty
The regulatory environment for physician practice M&A is increasingly complex. State-level oversight legislation, ongoing federal scrutiny of PE in healthcare, evolving Stark Law and Anti-Kickback enforcement priorities, and continued uncertainty around Medicaid reimbursement policy all represent headwinds that buyers must underwrite, and sellers must understand. PwC’s 2026 healthcare M&A outlook notes that buyers are demonstrating disciplined capital deployment in this environment, favoring high-quality, cash-generating assets with clear reimbursement visibility and avoiding areas subject to shifting regulatory dynamics. For OB/GYN practice owners, the practical implication is clear: a well-run, compliant practice with a diversified, commercially weighted payer mix will be a more attractive and more highly valued transaction target than a comparable practice with compliance risk or payer mix uncertainty.
The Window for Independent Practice Owners
The most important forecast for independent OB/GYN practice owners is this: the window of maximum investor interest in women’s health is open now, and the practices that engage in strategic planning today will be best positioned to participate on favorable terms. Nine major platforms are being built, hundreds of millions in PE capital are allocated specifically to women’s health acquisitions, and demographic demand for comprehensive women’s health services continues to accelerate. For practice owners who have invested years in building a high-quality, well-run clinical practice, the current environment represents a genuine opportunity to realize that value, with the right preparation, the right process, and the right advisors by their side.